Caspofungin (As Acetate)
| Evidence Level: L5 | Predicted Indications: 50 |
Quick Overview
| Item | Value |
|---|---|
| Drug Name | Caspofungin (As Acetate) |
| DrugBank ID | DB00520 |
| Brand Names (EU) | Cancidas (previously Caspofungin MSD) |
| Evidence Level | L5 |
| Predicted Indications | 50 |
| Top Prediction Score | 99.44% |
Approved Indication (EMA)
Treatment of invasive candidiasis in adult or paediatric patients; treatment of invasive aspergillosis in adult or paediatric patients who are refractory to or intolerant of amphotericin B, lipid formulations of amphotericin B and / or itraconazole. Refractoriness is defined as progression of infection or failure to improve after a minimum of seven days of prior therapeutic doses of effective antifungal therapy; empirical therapy for presumed fungal infections (such as Candida or Aspergillus) in
Predicted New Indications
TxGNN model predictions for potential drug repurposing:
| Rank | Indication | Score | Source |
|---|---|---|---|
| 1 | gastrin secretion abnormality | 99.44% | DL |
| 2 | punctate epithelial keratoconjunctivitis | 98.91% | DL |
| 3 | esophageal candidiasis | 98.15% | DL |
| 4 | abnormality of glucagon secretion | 97.67% | DL |
| 5 | HIV infectious disease | 96.73% | DL |
| 6 | simian immunodeficiency virus infection | 96.39% | DL |
| 7 | feline acquired immunodeficiency syndrome | 96.39% | DL |
| 8 | exposure keratitis | 95.75% | DL |
| 9 | congenital candidiasis | 95.18% | DL |
| 10 | candida glabrata | 95.18% | DL |
| 11 | neonatal candidiasis | 95.18% | DL |
| 12 | candidiasis, invasive | 95.03% | DL |
| 13 | candidemia | 94.98% | DL |
| 14 | polyclonal hyperviscosity syndrome | 94.63% | DL |
| 15 | hyperamylasemia | 94.63% | DL |
| 16 | epidemic keratoconjunctivitis | 94.25% | DL |
| 17 | blood group incompatibility | 94.25% | DL |
| 18 | premalignant hematological system disease | 93.88% | DL |
| 19 | congenital analbuminemia | 93.83% | DL |
| 20 | neurodevelopmental disorder with ataxic gait, absent speech, and decreased cortical white matter | 93.69% | DL |
Showing top 20 of 50 predictions.
About TxGNN Predictions
Prediction Sources
| Source | Description |
|---|---|
| KG | Knowledge Graph - Network topology-based associations |
| DL | Deep Learning - Neural network score prediction |
Evidence Levels
| Level | Definition |
|---|---|
| L1 | Multiple Phase 3 RCTs / Systematic Reviews |
| L2 | Single RCT or multiple Phase 2 trials |
| L3 | Observational studies / Large case series |
| L4 | Preclinical / Mechanistic / Case reports |
| L5 | AI prediction only (current) |
Clinical Validation Needed
Research Use Only: These predictions are computational hypotheses that require clinical validation. They should NOT be used for clinical decision-making.
Next Steps for Validation
- Literature Review: Search PubMed for existing evidence
- Clinical Trial Search: Check ClinicalTrials.gov for ongoing studies
- Mechanistic Analysis: Evaluate biological plausibility
- Preclinical Studies: Conduct in vitro/in vivo validation
- Clinical Trials: Design and conduct human studies
Data Access
- FHIR API:
/fhir/ClinicalUseDefinition/ - CSV Download: All Predictions
- GitHub: yao-care/EuTxGNN
Citation
If using this data, please cite:
@article{huang2023txgnn,
title={A foundation model for clinician-centered drug repurposing},
author={Huang, Kexin and others},
journal={Nature Medicine},
year={2023},
doi={10.1038/s41591-023-02233-x}
}
Disclaimer: This report is for research purposes only and does not constitute medical advice. Drug repurposing predictions require rigorous clinical validation before any therapeutic application.